Is TRT Safe for Your Heart? TRAVERSE Trial Results & FDA Changes

The question "Is testosterone replacement therapy safe for my heart?" has haunted men considering TRT for over a decade. Earlier studies suggested potential cardiovascular risks, leading to FDA black box warnings that made both patients and doctors cautious. But in 2023, the largest and most definitive cardiovascular safety study of testosterone therapy was published, fundamentally changing how we understand TRT's effects on heart health.

The TRAVERSE Trial: Setting the Record Straight

The Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response Study (TRAVERSE) was specifically designed to answer the cardiovascular safety question once and for all. Published in the New England Journal of Medicine, this double-blind, placebo-controlled trial followed 5,246 men aged 45-80 for an average of 33 months.

The results were clear: men receiving testosterone gel showed no statistically significant increase in the primary composite outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke compared to placebo. The hazard ratio was 0.96, meaning if anything, the testosterone group had slightly fewer major cardiovascular events—though this difference wasn't statistically significant.

FDA Response: Black Box Warnings Removed

Based on the TRAVERSE trial data, the FDA made a landmark decision in early 2025 to remove cardiovascular black box warnings from testosterone products. This regulatory change reflected the strongest evidence to date that appropriately prescribed TRT does not increase major cardiovascular risks in hypogonadal men.

The FDA's decision letter specifically cited the TRAVERSE trial's primary endpoint data, noting that the study "provides adequate evidence to support the cardiovascular safety of testosterone replacement therapy when used according to approved labeling."

What the Data Actually Shows

While the TRAVERSE trial cleared testosterone of major cardiovascular risks, it wasn't entirely without cardiovascular findings. The study identified two statistically significant differences that require monitoring:

Atrial Fibrillation: The testosterone group experienced atrial fibrillation at a rate of 2.2% versus 1.5% in the placebo group—a 7% relative increase. While still uncommon, this finding led to recommendations for baseline ECGs in men over 45 starting TRT.

Blood Pressure: Men receiving testosterone showed a small but consistent increase in systolic blood pressure averaging 0.3 mmHg compared to placebo after six months. This prompted the FDA to mandate blood pressure monitoring warnings on testosterone product labeling in February 2025.

Clinical Context: What This Means for Patients

The cardiovascular safety profile established by TRAVERSE fundamentally shifted clinical practice. Major medical societies, including the American Urological Association and the Endocrine Society, updated their guidelines in 2025 to reflect this new safety data.

For Men Without Heart Disease

The data strongly supports TRT safety in men with normal cardiovascular risk. The absence of increased major cardiovascular events, combined with known benefits for muscle mass, bone density, and quality of life, creates a favorable risk-benefit profile for appropriately diagnosed hypogonadal men.

For Men With Existing Heart Disease

Notably, the TRAVERSE trial included men with existing cardiovascular disease—about 35% of participants had coronary artery disease, and 14% had diabetes. These men showed no increased cardiovascular events with testosterone therapy, providing reassurance for this higher-risk population.

However, the trial did exclude men with recent myocardial infarction (within 6 months), unstable angina, stroke within 6 months, or severe heart failure. These conditions remain relative contraindications requiring individualized assessment.

Updated Monitoring Guidelines

The TRAVERSE trial findings led to refined monitoring protocols that balance safety with practical clinical care:

Baseline Assessment

• Comprehensive cardiovascular history and physical exam
• Blood pressure measurement
• ECG for men over 45 or those with cardiovascular risk factors
• Assessment of symptoms like chest pain, shortness of breath, or palpitations

Ongoing Monitoring

• Blood pressure at each visit (typically every 3-6 months)
• Annual cardiovascular risk reassessment
• Prompt evaluation of any new cardiac symptoms
• Consider repeat ECG if arrhythmia symptoms develop

Addressing Lingering Concerns

Despite the TRAVERSE trial's definitive results, some patients and providers remain cautious about TRT cardiovascular effects. This hesitancy is understandable given the decade of uncertainty following earlier, smaller studies that suggested potential risks.

Why Earlier Studies Were Misleading

Earlier observational studies that suggested cardiovascular risks were limited by selection bias, small sample sizes, and inadequate statistical power. The TRAVERSE trial's randomized, double-blind design with over 5,000 participants and extended follow-up provides the gold standard evidence needed for definitive safety assessment.

Individual Risk Assessment Remains Important

While the TRAVERSE trial provides strong population-level safety data, individual cardiovascular risk assessment remains crucial. Men with multiple cardiovascular risk factors, advanced coronary disease, or recent cardiac events should undergo cardiology consultation before starting TRT.

The Bottom Line on TRT Heart Safety

The cardiovascular safety question that has surrounded testosterone therapy for over a decade has been definitively answered by high-quality clinical trial data. The TRAVERSE trial's findings, combined with the FDA's 2025 regulatory changes, provide clear evidence that TRT does not increase major cardiovascular risks when appropriately prescribed and monitored.

However, the identification of modest increases in atrial fibrillation and blood pressure underscores the importance of proper cardiovascular screening and ongoing monitoring. Men considering TRT should undergo comprehensive cardiovascular assessment, and those with existing heart disease should involve their cardiologist in treatment decisions.

The era of cardiovascular uncertainty around TRT has ended, replaced by evidence-based confidence in its safety profile when used according to current medical guidelines.

Sources

• Cardiovascular Safety of Testosterone-Replacement Therapy - New England Journal of Medicine
• Testosterone Replacement Therapy in Men Aged 50 and Above - PMC
• Testosterone Replacement, Where Are We in 2025? - Trends in Urology & Men's Health
• Comments to the FDA on the Expert Panel on Testosterone Replacement Therapy - Public Citizen